. 2021 Aug 12;21(13):1–214.

Table A31:

Applicability of Studies Evaluating Cost-Effectiveness of Multi-gene Pharmacogenomic-Guided Treatment Versus Treatment as Usual in People With Major Depression

Author, Year, Country of Publication	Is the study population similar to the question?^a	Are the interventions similar to the question?^a	Is the health care system studied sufficiently similar to Ontario?^a	Were the perspectives clearly stated? If yes, what were they?^a	Are all direct effects included? Are all other effects included where they are material?^a	Are all future costs and outcomes discounted? If yes, at what rate?^a	Is the value of health effects expressed in terms of quality-adjusted life-years?^a	Are costs and outcomes from other sectors fully and appropriately measured and valued?^a	Overall Judgment^b
Tanner et al, 2020, Canada⁷⁸	Partially	Partially	Yes	Unclear	Unclear	Yes, 3%	Yes	Partially	Partially applicable
Groessl et al, 2018, United States⁷⁹	Partially	Partially	No	Yes, societal	No	Yes, 3%	Yes	Partially	Partially applicable
Najafzadeh et al, 2017, United States⁸¹	Partially	Partially	No	Yes, societal	Yes	Yes, 3%	Yes	Partially	Partially applicable
Hornberger et al, 2015, United States⁸⁰	Partially	Partially	No	Partially	No	Yes, 3%	Yes	Partially	Partially applicable

Response options were “yes,” “partially,” “no,” “unclear,” and “NA” (not applicable).

Response options for overall judgment were “directly applicable,” “partially applicable,” or “not applicable.”